Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Scinai Immunotherapeutics Ltd. (SCNI)

Scinai: Director George Lowell resigns from board, stays on advisory board

Neutral Impact 2 of 5 leadership Written later

Director George Lowell resigned from the board of directors effective May 12, 2023, after serving since 2008. The filing states he did not resign over any disagreement with the company, and he will remain on the Scientific Advisory Board as a liaison between that board and the Board. The filing names the registrant as BiondVax Pharmaceuticals Ltd.; the company and Mr. Lowell are still negotiating his compensation for the new roles.

Key points

  • Mr. Lowell submitted his board resignation on May 10, 2023, effective May 12, 2023
  • He had served as a Board member since 2008; the Board chairman, Mark Germain, thanked him for 15 years of service
  • Mr. Lowell will stay on the Scientific Advisory Board and become a liaison between it and the Board
  • Compensation for his continuing and new roles is still under discussion

The filing

CompanyScinai Immunotherapeutics Ltd. (SCNI)
Form8-K, current report
Filed with the SECMay 11, 2023, 5:20 PM ET
Accession number0001213900-23-038612

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 11, 2023.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.